High Incidence of Oral Dysesthesias on a Trial of Gefitinib, Paclitaxel, and Concurrent External Beam Radiation for Locally Advanced Head and Neck Cancers
Authors:
- 1 December 2008
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Clinical Oncology
- Vol. 31 (6) , 557-560
Abstract
Objectives: To report a high incidence of oral mucosal dysesthesia occurring in patients on a pilot study of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa) in combination with paclitaxel (Taxol) and external beam radiation therapy for the treatment of locally advanced squamous cell carcinoma of the head and neck. Methods: Nine patients were enrolled on a pilot phase I trial of oral gefitinib 250 mg/d with 6 weekly doses of paclitaxel (36 or 45 mg/m2) and concurrent radiation therapy [66–76 Gray (Gy)]. All had stage III/IVA-B squamous cell carcinoma of the head and neck. Patients were evaluated twice weekly by physicians and daily by nursing for adverse events. Results: Six of 9 patients (67%) developed a grade 3 “burning” quality oral dysesthesia. These patients received at least 50 Gy (range 50–70 Gy) to the oral tongue. The patients without grade 3 oral dysesthesia received less than 50 Gy radiation to the oral tongue. The oral dysesthesia was exacerbated by the ingestion of neutral pH liquids such as water. Of the 6 patients, all eventually developed common toxicity criteria grade 3/4 mucositis; however, symptoms continued after resolution of the mucositis. Gabapentin (Neurontin) was administered to 2 patients as a treatment for painful mucosal neuropathy. Both patients had near resolution of symptoms despite the evolution of oral mucositis. Conclusions: Development of “burning”-type oral dysesthesia occurred in patients treated with the combination of gefitinib, paclitaxel, and external beam radiation of the oral tongue. This dysesthesia was improved by the use of gabapentin.Keywords
This publication has 36 references indexed in Scilit:
- Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: A Gynecologic Oncology Group studyGynecologic Oncology, 2006
- Adjuvant Therapy in Patients With Resected Poor-Risk Head and Neck CancerJournal of Clinical Oncology, 2006
- Radiotherapy for head and neck cancer: latest developments and future perspectivesCurrent Opinion in Oncology, 2006
- Burning mouth syndrome: Clinical presentation, diagnosis and treatmentAustralasian Journal of Dermatology, 2006
- Palliative Chemotherapie von Kopf-Hals-Tumoren: Aktueller Stand und neue EntwicklungenLaryngo-Rhino-Otologie, 2006
- Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC)Drugs of Today, 2006
- Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology GroupBreast Cancer Research and Treatment, 2005
- Gefitinib in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): The Expanded Access Protocol Experience at the University of PennsylvaniaCancer Investigation, 2005
- Neuronal Plasticity: Increasing the Gain in PainScience, 2000
- Psychische Aspekte der Glossodynie*DMW - Deutsche Medizinische Wochenschrift, 1978